Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain very poor. The aim of this study was to explore whether patients with normalized LDH after targeted therapy could benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Schouwenburg, Maartje G., Suijkerbuijk, Karijn P.M., Koornstra, Rutger H.T., Jochems, Anouk, van Zeijl, Michiel C.T., van den Eertwegh, Alfons J.M., Haanen, John B.A.G., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., de Groot, Jan Willem B., Hospers, Geke A.P., Kapiteijn, Ellen, Kruit, Wim H., Piersma, Djura, van Rijn, Rozemarijn S., ten Tije, Albert J., Vreugdenhil, Gerard, van der Hoeven, Jacobus J.M., Wouters, Michel W.J.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966631/
https://www.ncbi.nlm.nih.gov/pubmed/31817189
http://dx.doi.org/10.3390/cancers11121940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966631/
https://www.ncbi.nlm.nih.gov/pubmed/31817189
http://dx.doi.org/10.3390/cancers11121940

Ejemplares similares